Last edition
News about Clinical Trials
Ascletis Initiates US Phase 1 Study of Oral ASC36 for Obesity
Ascletis has initiated a US Phase 1 study of ASC36, an investigational oral amylin receptor peptide agonist developed using the company’s proprietary oral peptide delivery technology.
Clinical Trials | 09/09/2026 | By News Bureau
Bristol Myers Squibb’s arlo-cel demonstrated statistically significant and clinically meaningful responses in patients with quadruple-class exposed relapsed and refractory multiple myeloma.
Clinical Trials | 09/09/2026 | By News Bureau
Novartis Updates Phase 3 HARBOR Study of Del-desiran for DM1
Novartis reports del-desiran showed clinical activity in secondary endpoints and exploratory analyses in the phase 3 HARBOR study for DM1.
Clinical Trials | 09/09/2026 | By News Bureau
Rezubio Advances RZ-520 Into Phase 1 Trial Following FDA and NMPA Clearances
Rezubio has dosed the first cohort in a Phase 1 trial evaluating RZ-520, an investigational inhaled therapy for chronic respiratory diseases.
Clinical Trials | 08/09/2026 | By News Bureau
Suven Completes Phase 3 Enrollment of Masupirdine for Alzheimer's-Related Agitation
Suven Life Sciences completes enrollment in its global Phase 3 masupirdine trial, with 424 patients randomised to evaluate the therapy for agitation associated with Alzheimer’s dementia.
Clinical Trials | 05/09/2026 | By News Bureau
Tangram Therapeutics Advances TGM-312 into MASH Patient Cohorts in Phase 1/2 Trial
Tangram Therapeutics advances TGM-312 into MASH patient cohorts in its Phase 1/2 RESTORE-MASH trial while appointing Dr Sonya Montgomery as Chief Development Officer to drive its clinical pipeline.
Clinical Trials | 05/09/2026 | By News Bureau
Novartis Reports Phase 3 Results for Pelacarsen in Cardiovascular Disease
Novartis reports phase 3 Lp(a)HORIZON topline results for pelacarsen, an investigational ASO targeting Lp(a) production in patients with cardiovascular disease (CVD).
Clinical Trials | 05/09/2026 | By News Bureau
Ultragenyx Announces Phase 3 Aspire Results in Angelman Syndrome
Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI).
Clinical Trials | 04/09/2026 | By News Bureau
Teva Pharmaceuticals Reports Positive Phase 2a Results for Anti-IL-15 Antibody in Celiac Disease
Teva Pharmaceuticals reports positive phase 2a results for TEV ‘408, an anti-IL-15 antibody that significantly prevented gluten-induced intestinal damage in celiac disease.
Clinical Trials | 03/09/2026 | By News Bureau
Novartis Remibrutinib Reduces Relapse Rates in Phase 3 RMS Trials
Novartis’ remibrutinib significantly reduces annualised relapse rates versus teriflunomide in phase 3 RMS trials, with a favorable safety profile and no liver safety signal.
Clinical Trials | 02/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy